Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,573
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,926.20 | 80.60 | -0.89% |
CAC 40 | 7,763.49 | 59.18 | -0.76% |
DAX 40 | 24,221.74 | 67.77 | -0.28% |
Dow JONES (US) | 44,402.17 | 59.98 | 0.14% |
FTSE 100 | 8,976.97 | 15.15 | -0.17% |
HKSE | 24,994.14 | 168.48 | 0.68% |
NASDAQ | 21,037.81 | 142.16 | 0.68% |
Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
NZX 50 Index | 12,961.51 | 81.11 | 0.63% |
S&P 500 | 6,321.70 | 24.91 | 0.40% |
S&P/ASX 200 | 8,668.20 | 89.00 | -1.02% |
SSE Composite Index | 3,559.79 | 25.31 | 0.72% |